The Pharmavanguard piece on ARS’s 2025 financials and Neffy update
Pharma 2025: From Nasal Sprays to Strategic Exchanges and Growth Leadership
The pharmaceutical and biotech sector in 2025 is being shaped less by headline pipeline announcements and more by the quiet but powerful moves around commercialization, leadership, and capital structure. Three recent updates on Pharmavanguard—on ARS Pharmaceuticals’ 2025 financials and Neffy nasal spray progress, Santhera’s appointment of Marc Clausse as Chief Commercial Officer, and Enzon’s extension […]
2 mins read